Article ID Journal Published Year Pages File Type
5104901 Value in Health 2016 7 Pages PDF
Abstract
Nivolumab is a cost-effective means of preventing downstream mortality and morbidity in patients with AM compared with ipilimumab in the Australian setting.
Keywords
Related Topics
Health Sciences Medicine and Dentistry Medicine and Dentistry (General)
Preview
A Cost-Effectiveness Analysis of Nivolumab Compared with Ipilimumab for the Treatment of BRAF Wild-Type Advanced Melanoma in Australia
Authors
, , , , , ,